Kelly Gold

CIK: 0002033333

Transaction Breakdown

Open Market Buys (P)3 (42.9%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CAMP

Camp4 Therapeutics Corp

Officer

XFOR

X4 Pharmaceuticals, Inc

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

CAMP
Camp4 Therapeutics Corp
Aug 31, 2026
Purchase(P)
Indirect
10K shares at avg. $3.96$40K
CAMP
Camp4 Therapeutics Corp
Aug 3, 2026
Purchase(P)
Direct
6.6K shares at avg. $1.65$11K
XFOR
X4 Pharmaceuticals, Inc
Jul 1, 2026
Award(A)
Stock Option (right to buy)
Direct
110K shares-
CAMP
Camp4 Therapeutics Corp
Apr 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
215K shares-
CAMP
Camp4 Therapeutics Corp
Dec 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
190K shares-
CAMP
Camp4 Therapeutics Corp
Sep 11, 2025
Purchase(P)
Direct
6.1K shares at avg. $1.65$10K
CAMP
Camp4 Therapeutics Corp
Apr 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-

		Type	Shares	Price		Ownership
Aug 31, 2026	CAMP Camp4 Therapeutics Corp	Purchase(P)	10,000	$3.96	$39,600	Indirect
Aug 3, 2026	CAMP Camp4 Therapeutics Corp	Purchase(P)	6,551	$1.65	$10,809	Direct
Jul 1, 2026	XFOR X4 Pharmaceuticals, Inc	Award(A) Stock Option (right to buy)	110,000	-	-	Direct
Apr 1, 2026	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	215,000	-	-	Direct
Dec 11, 2025	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	190,000	-	-	Direct
Sep 11, 2025	CAMP Camp4 Therapeutics Corp	Purchase(P)	6,060	$1.65	$9,999	Direct
Apr 1, 2025	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct

1-7 of 7 transactions

About Gold Kelly

Gold Kelly (SEC CIK 0002033333) files insider reports with the SEC as Chief Financial Officer of Camp4 Therapeutics Corp (CAMP) and Director of X4 Pharmaceuticals, Inc (XFOR).

Signal8 holds 9 ownership filings by Gold Kelly (2 Form 3, 7 Form 4), filed between Oct 10, 2024 and Sep 2, 2026. Those filings report 7 transactions, from Apr 1, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gold Kelly's filings is in WATERTOWN, MA.

Recent filings by Gold Kelly

Aug 31, 2026: Open-market purchase of CAMP shares (Form 4, code P).
Aug 3, 2026: Open-market purchase of CAMP shares (Form 4, code P).
Jul 1, 2026: Grant or award of XFOR derivative securities (Form 4, code A).
Apr 1, 2026: Grant or award of CAMP derivative securities (Form 4, code A).
Dec 11, 2025: Grant or award of CAMP derivative securities (Form 4, code A).

Other insiders filing for Camp4 Therapeutics Corp (CAMP)

Schwab Andrew J., Director
Tardiff Daniel, Chief Scientific Officer
5AM Partners VI, LLC, 10% Owner
Young Richard A, Director
Maricich Yuri, Chief Medical Officer
Mandel-Brehm Josh, Chief Executive Officer

How to read Form 4 transaction codes